These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31027700)

  • 21. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.
    Tembuyser L; Tack V; Zwaenepoel K; Pauwels P; Miller K; Bubendorf L; Kerr K; Schuuring E; Thunnissen E; Dequeker EM
    PLoS One; 2014; 9(11):e112159. PubMed ID: 25386659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of an RNA extraction-free test for the multiplexed detection of
    Damiola F; Alberti L; Mansuet-Lupo A; Damotte D; Hofman V; Tixier L; Penault-Llorca F; Rouquette I; Vignaud JM; Cazes A; Forest F; Begueret H; Gibault L; Badoual C; Cayre A; Taranchon-Clermont E; Duc A; Mc Leer A; Lantuejoul S
    Expert Rev Mol Diagn; 2023; 23(12):1283-1291. PubMed ID: 37906110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
    Sun W; Zheng J; Zhou J; Zhou J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive NGS profiling to enable detection of
    Clavé S; Jackson JB; Salido M; Kames J; Gerding KMR; Verner EL; Kong EF; Weingartner E; Gibert J; Hardy-Werbin M; Rocha P; Riera X; Torres E; Hernandez J; Cerqueira G; Nichol D; Simmons J; Taus Á; Pijuan L; Bellosillo B; Arriola E
    Front Oncol; 2023; 13():1225646. PubMed ID: 37927472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patients.
    Yang L; Ling Y; Guo L; Ma D; Xue X; Wang B; Li J; Ying J
    Chin J Cancer Res; 2016 Oct; 28(5):495-502. PubMed ID: 27877008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of NTRK fusions by RNA-based nCounter is a feasible diagnostic methodology in a real-world scenario for non-small cell lung cancer assessment.
    de Oliveira Cavagna R; de Andrade ES; Tadin Reis M; de Paula FE; Noriz Berardinelli G; Bonatelli M; Ramos Teixeira G; Garbe Zaniolo B; Mourão Dias J; da Silva FAF; Baston Silva CE; Xavier Reis M; Lopes Maia E; de Alencar TS; Jacinto AA; da Nóbrega Oliveira REN; Molina-Vila MA; Ferro Leal L; Reis RM
    Sci Rep; 2023 Dec; 13(1):21168. PubMed ID: 38036758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).
    Lee SY; Cho HJ; Choi J; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Kim TJ; Sung YE; Hwang Y; Lee E; Ahn DH; Choi JY; Lim JU; Park CK; Kim SW; Kim SJ; Koo IS; Jung WS; Lee SH; Yeo CD; Lee DW
    J Exp Clin Cancer Res; 2023 Nov; 42(1):309. PubMed ID: 37993887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
    Lim JJ; Chen EY; Schaub SK; Wagner MJ
    Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of
    Mehta A; Saifi M; Batra U; Suryavanshi M; Gupta K
    Lung Cancer (Auckl); 2020; 11():19-25. PubMed ID: 32158297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System.
    Makarem M; Ezeife DA; Smith AC; Li JJN; Law JH; Tsao MS; Leighl NB
    Curr Oncol; 2021 Aug; 28(5):3268-3279. PubMed ID: 34449580
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.
    Kang DW; Park SK; Yu YL; Lee Y; Lee DH; Kang S
    ESMO Open; 2024 Jan; 9(1):102200. PubMed ID: 38194884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Intergenic Region (chr2: 30,316,870)-
    Zhou D; Ying J; Hu S; Li J; Liu H
    Onco Targets Ther; 2024; 17():261-265. PubMed ID: 38558847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.
    Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
    Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study.
    Mo Y; Lin L; Zhang J; Zhong Y; Zhang T; Zhong C; Yan J; Kuang J; Guo Q; Tan J; Li D; Wu M
    Pathol Res Pract; 2022 Oct; 238():154105. PubMed ID: 36099717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
    Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
    Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
    Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
    [No Abstract]   [Full Text] [Related]  

  • 37. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
    Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.
    Chen Q; Zhang J; Wang X; Zong W; Sun L; Qin J; Yin Y
    Front Oncol; 2023; 13():1227980. PubMed ID: 38023218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Joint DNA-RNA-based NGS for diagnosis and treatment of a rare
    Wang R; Liu Y; Yu X; Wang W; Liu J
    Front Immunol; 2024; 15():1386561. PubMed ID: 38957460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Catalog of 5' Fusion Partners in
    Ou SI; Zhu VW; Nagasaka M
    JTO Clin Res Rep; 2020 Mar; 1(1):100015. PubMed ID: 34589917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.